You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
10 December 2019
Sanofi’s new chief executive officer Paul Hudson is restructuring the company into three “core” global business units and a “standalone” Consumer Healthcare operation.
25 November 2019
Media reports suggest Sanofi is considering a range of strategic options, including divestment, for its Consumer Healthcare business, but no final decision has been made.
15 November 2019
Sanofi Consumer Healthcare has an option on technology from ResApp Health, which is developing smartphone applications for the diagnosis and management of respiratory disease.
8 November 2019
Sanofi's Consumer Healthcare business reported worldwide sales up by 0.4% at constant exchange rates in the third quarter of 2019. The company said growth had been curbed by a voluntary recall of Zantac, non-core brand divestments, and tightening regulatory requirements, particularly in Europe.
2 September 2019
Italy's Angelini Pharma has acquired two brands from Sanofi Consumer Healthcare in Germany and Austria for EUR47 million (USD51 million).
5 August 2019
Sanofi's Consumer Healthcare business reported worldwide sales up by 1.1% at constant exchange rates in the second quarter of 2019. The company said brand divestments and tightening regulatory requirements, particularly in Europe, had reduced growth by around two percentage points.
23 July 2019
Sanofi has gained exclusive OTC rights to Roche's Tamiflu (oseltamivir) for prevention and treatment of flu in the US.
19 June 2019
Sanofi and Google are creating a virtual Innovation Lab with the aim of "radically transforming how future medicines and health services are delivered by tapping into the power of emerging data technologies".
10 June 2019
Sanofi has announced that Paul Hudson will replace Olivier Brandicourt as chief executive officer from 1 September 2019.
29 April 2019
Sanofi's Consumer Healthcare business reported worldwide sales up by 0.6% at constant exchange rates in the first quarter of 2019. The company said growth in the Emerging Markets region had offset lower sales in Developed Markets and the impact of divesting non-core brands.